SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI11/3/2006 8:31:16 PM
  Read Replies (1) of 671
 
09:42 am Alnylam Pharmaceuticals: Bear Stearns downgrades Outperform to Peer Perform. Bear Stearns downgraded ALNY to Peer Perform from Outperform based on the significant appreciation of shares due to the acquisition of a competitor, and its implications for a take-out of ALNY. The firm believes the majority of major pharma/biotech firms are awaiting add'l validation of the RNAi platform, while Merck had been one of the most outspoken proponents. They do not view an acquisition of ALNY to be probable in the near-term, until positive efficacy data from its lead candidate for RSV infection, ALN-RSV01, suggests proof-of-concept; they expect the first read of efficacy from its experimental infection study around mid-2007.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News